Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOL-463 for suppression of recurrent bacterial vaginosis
NCT03930745Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TOL-463 in bacterial vaginosis (BV), sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2019; status: completed.
02
Drugs
TOL-463
03
Conditions
bacterial vaginosis (BV)
Beyond the preview
Go deeper on NCT03930745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03930745.